Premium
Iminodiacetic Acid as a Novel Metal‐Binding Pharmacophore for New Delhi Metallo‐β‐lactamase Inhibitor Development
Author(s) -
Chen Allie Y.,
Thomas Caitlyn A.,
Thomas Pei W.,
Yang Kundi,
Cheng Zishuo,
Fast Walter,
Crowder Michael W.,
Cohen Seth M.
Publication year - 2020
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000123
Subject(s) - pharmacophore , chemistry , derivatization , iminodiacetic acid , combinatorial chemistry , stereochemistry , electrospray ionization , chelation , mass spectrometry , chromatography , organic chemistry
The fungal natural product aspergillomarasmine A (AMA) has been identified as a noncompetitive inhibitor of New Delhi metallo‐β‐lactamase‐1 (NDM‐1) that inhibits by removing Zn II from the active‐site. The nonselective metal‐chelating properties and difficult synthesis and derivatization of AMA have hindered the development of this scaffold into a potent and selective inhibitor of NDM‐1. Iminodiacetic acid (IDA) has been identified as the metal‐binding pharmacophore (MBP) core of AMA that can be leveraged for inhibitor development. Herein, we report the use of IDA for fragment‐based drug discovery (FBDD) of NDM‐1 inhibitors. IDA (IC 50 =120 μM) was developed into inhibitor 23 f (IC 50 =8.6 μM, K i =2.6 μM), which formed a ternary complex with NDM‐1, as evidenced by protein thermal‐shift and native‐state electrospray ionization mass spectrometry (ESI‐MS) experiments. Combining mechanistic analysis with inhibitor derivatization, the use of IDA as an alternative AMA scaffold for NDM‐1 inhibitor development is detailed.